BioSpace News Archive

Nectar, an innovative and comprehensive allergy care platform, announced their $8 million seed round led by Juxtapose and Obvious Ventures, who are co-building the company alongside Founder and CEO Kenneth Chahine, Ph.D.

Codagenix Inc. today announced interim Phase 1 data indicating induction of T cell immunity against highly-conserved antigens of the SARS-CoV-2 Omicron variant following two doses of its intranasal vaccine, CoviLiv (previously called Covi-Vac).

Aldeyra Therapeutics, Inc. today reported recent corporate highlights and financial results for the year ended December 31, 2021.

AVROBIO, Inc. today reported financial results for the fourth quarter and year ended Dec. 31, 2021, and provided a business update.

Resverlogix Corp. (“Resverlogix”) (TSX:RVX) today announced the publication of an article entitled “ BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Study ” in the prestigious American Journal of Respiratory and Critical Care Medicine – which has an impact factor of 21.4.

Cullinan Oncology, Inc. today reported on recent and upcoming business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2021.

ZAP Surgical Systems, Inc. today announced that Unicancer , a leading academic promoter of oncology clinical trials and medical equipment purchasing health cooperation group for 19 French comprehensive cancer centers, has selected the ZAP-X ® Gyroscopic Radiosurgery ® platform for cranial stereotactic radiosurgery.

Vera Therapeutics, Inc., a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, will host a business update call at 8:00 a.m. ET on March 24, 2022.

“Throughout 2021, we continued to make steady progress in developing our comprehensive, next-generation iPSC-based cell therapy platform, executed on our powerful discovery engine, and we believe we are positioned to transition to a clinical stage company in 2022.

InMed Pharmaceuticals Inc. today announces that its Chief Financial Officer, Mr. Bruce Colwill, will be retiring and will be stepping down from his position at the Company effective March 31, 2022.